【摘要】 非小细胞肺癌（non-small cell lung cancer, NSCLC）患者的预后主要取决于其TNM分期、年龄、身体状况、合并症等，然而相似状态和相同分期的患者经过临床规范治疗后，患者生活质量和生存期仍有不同。血小板与淋巴细胞比值（platelet to lymphocyte ratio, PLR）、中性粒细胞与淋巴细胞比值（neutrophil to lymphocyte ratio, NLR）是机体系统性炎症指标，在NSCLC的发生发展中有重要作用，其变化与NSCLC的预后相关。目前已经有大量文章报道了PLR和/或NLR与NSCLC患者的预后关系，因此，本文就此进行综述，为临床诊疗及患者预后判断提供新思路。更多还原

【Abstract】 The prognosis of patients with non-small cell lung cancer(NSCLC) mostly depends on the TNM stage, age, physical condition, comorbidities, etc. However, after standard clinical treatment,the quality of life and the survival of patients with similar status and the same stage are still different. Platelet to lymphocyte ratio(PLR) and neutrophil to lymphocyte ratio(NLR) represent biomarkers of systemic inflammation, which play important roles in the occurrence and development of NSCLC. The changes of NLR and PLR are associated with the prognosis of NSCLC. At present, a large number of articles have introduced the relationship between PLR and/or NLR and the prognosis of NSCLC patients.Therefore, this issue has been review in order to provide ideas for clinical diagnosis and treatment and the prognosis judgment of patients.更多还原